Skip to main content
. Author manuscript; available in PMC: 2024 Feb 1.
Published in final edited form as: Clin Gastroenterol Hepatol. 2022 Feb 3;21(2):415–423.e4. doi: 10.1016/j.cgh.2022.01.047

Table 4:

Concordance between GALAD and HES algorithms results (based on thresholds corresponding to 10% screening-level false positive rate) within 6, 12 and 24 months prior to diagnosis in patients with any stage HCC.

Any Stage HCC
6 months 12 months 24 months
HES positive HES negative HES positive HES negative HES positive HES negative
GALAD positive 16 (48.5%) 3 (9.1%) 20 (47.6%) 3 (7.1%) 21 (42.5%) 5 (10.2%)
GALAD positive 5 (15.2%) 9 (27.3%) 5 (11.9%) 14 (33.3%) 8 (16.3%) 15 (30.6%)
Early Stage HCC
HES positive HES negative HES positive HES negative HES positive HES negative
GALAD positive 15 (57.7%) 3 (11.5%) 18 (60.0%) 3 (10.0%) 18 (52.9%) 5 (14.7%)
GALAD positive 1 (3.8%) 7 (26.9%) 1 (3.3%) 8 (26.7%) 2 (5.9%) 9 (26.5%)